Breast cancer is the largest field at ASCO — 498 studies in 2026, more than colorectal and lung combined for many sub-questions. That scale makes it the best place to watch the modality rotation play out at high resolution. The radar shows a field rotating decisively toward antibody-drug conjugates and a revived PI3K/AKT axis, while the CDK4/6 era that defined the last decade quietly consolidates.
The biggest track keeps growing
Breast-cancer studies rose from 396 in 2024 to 455 in 2025 to 498 in 2026. Underneath that total, the composition is shifting. Antibody-drug conjugates — led by trastuzumab deruxtecan (T-DXd), which is breast-heavy, and sacituzumab govitecan, anchored in triple-negative disease — are the dominant and still-rising force. Meanwhile the CDK4/6 inhibitor class, the backbone of HR-positive treatment for a decade, is contracting in study volume as it consolidates around its winners.
Four currents reshaping the field
The radar resolves the 498 studies into a handful of clear currents — what's rising, what's being created, and what's maturing.
| Breast-cancer driver | What the radar shows | Signal |
|---|---|---|
| Antibody-drug conjugates | T-DXd breast-heavy (≈40 of 85 studies); sacituzumab govitecan TNBC-anchored | Dominant & growing |
| HER2-low / HER2-ultralow | 18 ASCO 2026 titles explicitly name HER2-low; a new biomarker stratum | New market created |
| PI3K/AKT pathway | capivasertib (ELEVATE), gedatolisib (VIKTORIA-1), inavolisib in PIK3CA-mutant disease | Re-energized |
| CDK4/6 inhibitors | palbociclib 44→27; class 95→64 — consolidating around winners | ▼ Maturing |
| SERDs (elacestrant et al.) | Oral SERD combinations with AKT/PI3K inhibitors entering the program | ▲ Emerging |
1. HER2-low (and now HER2-ultralow) keeps splitting the market
The single most important structural change in breast cancer is the redefinition of "HER2-positive." Once a binary, HER2 is now a spectrum, and T-DXd's activity in HER2-low — and increasingly HER2-ultralow — disease has created entirely new addressable populations out of patients previously classified as HER2-negative. Eighteen ASCO 2026 study titles explicitly name HER2-low, a biomarker stratum that barely existed a few years ago. Each redefinition expands the eligible population for HER2-directed ADCs.
2. The PI3K/AKT axis is re-energized
After years in which toxicity blunted the PI3K-pathway story, the axis is back — and the radar shows it. The headline is VIKTORIA-1, a late-breaking Phase 3 trial of gedatolisib (a pan-PI3K/mTOR inhibitor) plus fulvestrant with or without palbociclib in PIK3CA-mutant, HR-positive disease after CDK4/6 progression. VIKTORIA-1 met its primary progression-free-survival endpoint versus alpelisib plus fulvestrant, with the doublet also delivering clinically meaningful benefit. Alongside it, capivasertib (the approved AKT inhibitor, studied in ASCO 2026 in the ELEVATE combination with the oral SERD elacestrant) and inavolisib round out a re-energized pathway.
3. ADCs are the new backbone question
With T-DXd and sacituzumab govitecan both established, the field's questions have moved to sequencing: which ADC first, can you use a second ADC after the first, and how do payload classes interact. Real-world studies on ADC-after-ADC sequencing are a notable ASCO 2026 theme — a sign of a modality that has graduated from "does it work" to "how do we optimize a multi-ADC treatment journey."
4. CDK4/6 is maturing, not dying
Palbociclib studies fell from 44 to 27 over two years and the class contracted from 95 to 64. This is not a failure signal — it is consolidation. The class is settling around its strongest agents and its proven HR-positive setting, while the field's marginal attention flows to the ADC and PI3K/AKT stories.
The commercialization read
For BD teams: breast cancer is the most competitive field in oncology — a 498-study arena where differentiation is expensive. The live white space is in biomarker-defined sub-populations (HER2-ultralow, specific PI3K-pathway alterations) and in sequencing strategy (next-line ADCs, oral SERD combinations). For investors: VIKTORIA-1 reopening the PI3K-pathway opportunity, and the continued HER2-low market expansion, are the two developments most likely to move competitive share over the next 18 months.
Explore the underlying data
Every number above is live and pivotable on the Knitify ASCO Radar — analyze the 7,222 studies in the ASCO 2026 program by drug, indication, sponsor, or trial-in-progress status, and compare year over year against 2025 and 2024. Filter the board to breast cancer to reproduce every count in this article. The radar links to each study on the official ASCO program; it does not reproduce copyrighted text.
Methodology & scope: figures in this article are structured signals the Knitify ASCO Radar derives from the publicly released ASCO 2026 scientific program (7,222 studies presented; 6,511 in 2025; 5,885 in 2024) — counting how many studies reference a given drug, indication, or modality class. They quantify research attention and momentum, not clinical efficacy or market share. Named trial results are quoted from public company press releases, the ASCO press program, and peer-reviewed journals (cited below). The radar does not reproduce any copyrighted text — it links to each study on the official ASCO program. This is editorial commentary on public data — not investment, legal, regulatory, or medical advice.